LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling.
Paulis
Ludovit
L
Simko
Fedor
F
D000818:Animals; D001794:Blood Pressure; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000517:prevention & control*; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D009569:Nitric Oxide / Q000502:physiology; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D052250:Nitric Oxide Synthase Type III / Q000502:physiology*; D020257:Ventricular Remodeling / Q000187:drug effects*
C503157:LA 419; D020030:Nitric Oxide Donors; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D007548:Isosorbide Dinitrate